Who
Amit Etkin
President and CEO
Company insider
Files Form 4 as: President and CEO, Alto Neuroscience.
In numbers
- Trades disclosed
- 20
- Buys
- 1
- Sells
- 0
- Bought
- $50K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Feb 2024
- Last trade
- 14 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 15 May 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code G | —400,000 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code G | —400,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code F | $123K6,227 at $19.69 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code F | $123K6,227 at $19.69 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —306,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —306,000 at $0.00 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,620 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —34,620 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —247,290 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —247,290 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —223,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —223,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —215,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —215,000 | filing |
| 5 Feb 2025filed 7 Feb 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —215,000 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —223,000 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code A | —34,711 at $0.00 | filing |
| 6 Feb 2024filed 7 Feb 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code C | —25,000 at $0.00 | filing |
| 6 Feb 2024filed 7 Feb 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code C | —11,777 | filing |
| 6 Feb 2024filed 7 Feb 2024 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Bought | $50K3,125 at $16.00 | filing |
News
No headline names them, or the companies they trade most, lately.